Breast cancer is the most common malignant neoplasm in women. The presence of hormone receptors on malignant cells influences the prognosis and application of the appropriate therapy. The receptor status of estrogen and proestrogen was tested in relation to the age of the patients and clinical stage of disease. The analysis comprised 449 patients with breast cancer, mean age 56.2±12 years, treated at the Oncology Clinic CC Nis and operated at the Surgery Clinic CC Nis. The patients were divided into four groups: I group - 246 patients with ER+/PR+ receptors; II group - 45 patients with ER+/PR- receptors; III group - 20 patients with ER-/PR+ receptors and IV group - 109 patients with ER-/PR- receptors. The clinical stage of the tumor was described as operative, locally advanced and metastatic, plus patient age stratification. The receptor status was determined in 440 patients, while it remained unknown in 9(2%) cases. In regard to the total number of patients, ER+/PR+ was registered in 54.7% of the patients, ER+/PR- in 14.0%, ER-/PR+ in 4.5%, and ER-/PR- in 24.3% The most common one was a hormone-sensitive breast tumor (76%) compared to non-sensitive tumors (24%). Of hormone-sensitive tumors, the most common were Er+/Pr+ tumors in 58% of the patients, and the least common Er-/Pr+ tumors in 4%. In women younger than 40, hormonal non-sensitivity dominates (55%). Hormone-sensitive tumors are more present as the patients grow older, and they dominate in patients older than the age of 70. Operative tumor was found in 78.64% of the patients, locally advanced in 18.18%, and metastasis in 3.18%. Hormone-sensitive tumors are far more often operative and less locally advanced than non-sensitive tumors (Hi=8.2, p
Full Text Finder